Bioactive or Drug-Eluting Stents in 75 Years or Older Patients: The BIODES-75 Registry

BackgroundTiNO-coated BAS have demonstrated competitive outcomes compared to drug-eluting stents (DES). These devices allow short antiplatelet regimens and may be a good option for the growing elderly population undergoing percutaneous coronary intervention (PCI).MethodsMulticenter observational trial in routine clinical practice. A propensity-score matched analysis compared a prospective cohort of patients ≥ 75 years undergoing PCI with BAS, with a contemporary and retrospective cohort treated with last-generation DES. The co-primary endpoints of the study were the Target-Lesion-Failure (Cardiac death, non-fatal myocardial infarction, or target lesion revascularization) and Major Adverse Cardiovascular Events (total death, non-fatal myocardial infarction, stroke, or new revascularization) at 1 year.ResultsWhole population included 1000 patients, and 326 patients in each group were matched for analysis. No differences in primary endpoints were found: TLF 10.4% vs. 11% (HR 0.96 (Confidence Interval 95%, 0.36–1.7; p = 0.87)) and MACE 16.3% vs. 17.2% (HR 0.98 (Confidence Interval 95%; 0.3–1.5, p = 0.93)). Patients treated with BAS received shorter antiplatelets regimens (dual antiplatelet therapy at 1 year, 25.7% vs. 70.6%, p = 0.0001), and they presented lower incidence of bleeding (3.7% vs. 11.7%, HR 0.3 (IC 95% 0.16–0.6, p = 0.001)).ConclusionIn this real-life registry of patients ≥ 75 years, BAS were similar to the latest-generation DES in terms of efficacy and reduced the duration of the antithrombotic therapy, lowering bleeding events.     

Effectiveness and Safety of Golimumab for Patients ≥75 Years Old with Rheumatoid Arthritis

ObjectiveTreatment of elderly patients with rheumatoid arthritis (RA) has been controversial because they often have serious comorbidities and cannot use methotrexate (MTX). In Japan, golimumab (GLM) 100 mg without MTX is approved. We investigated the effectiveness and safety of GLM in elderly patients with RA. Methods The GLM survival rate was evaluated using the Kaplan-Meier method. Disease activities, laboratory findings, and treatments were evaluated. Patients We enrolled 168 patients with RA in our hospital. Using age ≥75 years old to identify elderly patients, younger (n=111) and elderly (n=57) groups were established. Elderly patients were divided into 2 groups according to the MTX treatment status (with, n=27; without, n=25). Results The GLM survival rates were 80.8% and 82.3% in elderly and younger patients, respectively (p=0.762). At 52 weeks, the Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) was improved in elderly patients (4.26 vs. 3.31, p＜0.001); the Health Assessment Questionnaire Disability Index (HAQ-DI) was unchanged (1.12 vs. 0.88, p=0.694). When elderly patients were compared according to the MTX treatment status, the DAS28-ESR had improved in both groups (with MTX: 3.82 vs. 2.68, p＜0.001; without MTX: 4.76 vs. 4.25, p=0.026); however, the HAQ-DI had not. The GLM survival rates at 52 weeks were 85% and 76% in patients with and without MTX, respectively. Conclusion In elderly patients with RA, GLM was effective, regardless of MTX treatment status, but it did not affect the HAQ-DI. GLM survival rates were comparable between elderly and younger patients. GLM may be a suitable option for elderly patients with RA who cannot use MTX.     

年龄＞75岁老年患者冠状动脉介入治疗随访研究

目的评价年龄>75岁老年患者冠状动脉介入治疗术后远期效果,了解老年人介入术后的有效性。方法 351例行冠状动脉介入患者,按年龄分为普通老年组(≤75岁,n=180)和>75岁老年组(n=171),了解年龄>75岁患者一般临床资料、冠状动脉造影情况、冠状动脉介入术后1年心肌梗死发生率、再次冠状动脉介入率及不良事件发生率等。结果 >75岁老年组高血压、糖尿病患病率升高(P<0.05),冠状动脉病变以多支病变为主(P<0.05),左回旋支和右冠状动脉病变明显高于普通老年组(P<0.05),冠状动脉介入术后心源性病死率、再次冠状动脉介入治疗率、冠状动脉搭桥率等明显高于普通老年组(P<0.05)。结论年龄>75岁患者冠心病多并发高血压、糖尿病等,冠状动脉病变重而且复杂,冠状动脉介入治疗术后心血管发生率升高,不能减少远期死亡率。